INSM INSMED Inc

Nasdaq insmed.com


$ 201.86 $ 4.22 (2.14 %)    

Tuesday, 18-Nov-2025 15:57:57 EST
QQQ $ 599.40 $ 0.00 (0 %)
DIA $ 462.07 $ 0.00 (0 %)
SPY $ 662.89 $ 0.00 (0 %)
TLT $ 88.89 $ 0.00 (0 %)
GLD $ 378.26 $ 0.00 (0 %)
$ 201.62
$ 195.51
$ 201.65 x 5
$ 205.44 x 1
-- - --
$ 60.40 - $ 203.65
2,412,985
na
43B
$ 0.90
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-30-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 02-20-2025 12-31-2024 10-K
5 10-31-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 02-22-2024 12-31-2023 10-K
9 10-26-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 10-27-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-17-2022 12-31-2021 10-K
17 10-28-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 10-29-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 04-30-2020 03-31-2020 10-Q
24 02-25-2020 12-31-2019 10-K
25 10-30-2019 09-30-2019 10-Q
26 08-01-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 02-22-2019 12-31-2018 10-K
29 10-30-2018 09-30-2018 10-Q
30 08-02-2018 06-30-2018 10-Q
31 05-02-2018 03-31-2018 10-Q
32 02-23-2018 12-31-2017 10-K
33 11-02-2017 09-30-2017 10-Q
34 08-03-2017 06-30-2017 10-Q
35 05-03-2017 03-31-2017 10-Q
36 02-23-2017 12-31-2016 10-K
37 11-03-2016 09-30-2016 10-Q
38 08-04-2016 06-30-2016 10-Q
39 05-05-2016 03-31-2016 10-Q
40 02-25-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 insmed-wins-eu-approval-for-brinsupri-the-first-treatment-for-non-cystic-fibrosis-bronchiectasis-in-patients-12-years-of-age-and-older-with-two-or-more-exacerbations-in-the-prior-12-months

— Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damage —— BR...

 druckenmiller-opens-position-in-amazon-closes-microsoft--heres-more-of-duquesnes-biggest-q3-moves

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven...

 wells-fargo-maintains-overweight-on-insmed-raises-price-target-to-217

Wells Fargo analyst Tiago Fauth maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $171 to $217.

 goldman-sachs-maintains-buy-on-insmed-raises-price-target-to-225

Goldman Sachs analyst Andrea Tan maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $196 to $225.

 ubs-maintains-buy-on-insmed-raises-price-target-to-223

UBS analyst Trung Huynh maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $194 to $223.

 rbc-capital-maintains-outperform-on-insmed-raises-price-target-to-215

RBC Capital analyst Leonid Timashev maintains Insmed (NASDAQ:INSM) with a Outperform and raises the price target from $139 t...

 meta-tumbles-10-google-marks-historic-rally-whats-moving-markets-thursday

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the me...

 insmed-raises-fy2025-global-arikayce-sales-guidance-from-405m-425m-to-420m-430m

Balance Sheet, Financial Guidance, and Planned InvestmentsAs of September 30, 2025, Insmed had cash, cash equivalents, and mark...

 insmed-q3-eps-175-misses-138-estimate-sales-142342m-beat-115604m-estimate

Insmed (NASDAQ:INSM) reported quarterly losses of $(1.75) per share which missed the analyst consensus estimate of $(1.38) by 2...

 a-preview-of-insmeds-earnings
A Preview Of Insmed's Earnings
10/29/2025 18:01:52

 b-of-a-securities-maintains-buy-on-insmed-raises-price-target-to-187

B of A Securities analyst Jason Zemansky maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $142 to ...

 insmed-to-present-six-abstracts-from-phase-3-aspen-study-of-brinsupri-at-chest-2025

—Data on Structural Lung Changes from a High-Resolution CT Substudy to be Presented as Late-Breaker——Additional Analyses Will H...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION